Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06629779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

StatusRecruiting
PhasePhase 3
SponsorPfizer
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 233 to 231
  2. Trial sites reduced: 236 → 233 locations
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 7 of 20 entries
    • Publications: details revised at 1 of 1 entry
  3. Site details revised at 1 of 236 sitesv42
  4. Study sites: 237 to 236v41
  5. Trial sites reduced: 240 → 237 locationsv40
Show 38 earlier versionsHide 38 earlier versions
  1. Study sites: 241 to 240v39
  2. Study sites: 240 to 241v38
  3. Site details revised at 2 of 240 sitesv37
  4. Study sites revised (240)v36
  5. Study sites: 241 to 240v35
  6. Re-verified, no change to tracked fieldsv34
  7. Study sites revised (241)v33
  8. Study sites: 240 to 241v32
  9. Study sites: 239 to 240v31
  10. Study sites: 240 to 239
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: 18 to 20
    v30
  11. Study sites: 241 to 240v29
  12. Site details revised at 3 of 241 sitesv28
  13. Study sites: 243 to 241v27
  14. Study sites: 242 to 243
    • Primary completion date: Jul 24, 2026 to Dec 2, 2026
    v26
  15. Study sites: 239 to 242v25
  16. Study sites: 229 to 239v24
  17. Study sites: 230 to 229v23
  18. Study sites: 228 to 230v22
  19. Study sites: 226 to 228v21
  20. Site details revised at 3 of 226 sitesv20
  21. Study sites: 213 to 226v19
  22. Study sites: 204 to 213v18
  23. Study sites: 186 to 204v17
  24. Study sites: 176 to 186v16
  25. Study sites: 168 to 176v15
  26. Eligibility criteria shortened, about 15 wordsv14
  27. Study sites: 155 to 168v13
  28. Study sites: 145 to 155v12
  29. Study sites: 105 to 145v11
  30. Study sites: 57 to 105v10
  31. Study sites: 30 to 57v9
  32. Study sites: 26 to 30v8
  33. Study sites: 22 to 26v7
  34. Study sites: 24 to 22v6
  35. Study sites: 23 to 24v5
  36. Study sites: 19 to 23v4
  37. Study sites: 16 to 19
    • Start date: Oct 2024 to Oct 22, 2024
    v3
  38. Study sites: 5 to 16
    • Start date: Sep 24, 2024 to Oct 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
436 trials monitored
See 32 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Trial Details
NCT Number NCT06629779
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Metastatic Castration-Resistant Prostate Cancer
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov